Common questions about Omidria (KetorolacPhenylephrine hydrochloride) (FAQ)
Q: How quickly does the effect of Omidria wear off after the surgery is complete?
Official studies indicate that the reduction of acute postoperative ocular pain was observed to be statistically significant during the initial 10 to 12 hours following the procedure compared to placebo. However, the exact duration of the pupil-dilating effect is not precisely defined in regulatory documents. It is temporary, and patients are typically advised not to drive or operate machinery until their vision has cleared.
Q: Is it safe to use Omidria during pregnancy?
Official product information indicates that use during late pregnancy, specifically the third trimester, must be considered with caution or avoided due to potential risks associated with the NSAID (ketorolac) component. For the first and second trimesters, there is a lack of specific data, and official guidance suggests using it only if clearly needed.
Q: Is Omidria used for patients under the age of 18?
Regulatory guidance on pediatric use differs depending on the jurisdiction. The U.S. FDA has established that safety and effectiveness are supported for pediatric patients from birth through 17 years old. Conversely, the European Medicines Agency (EMA) states that safety and efficacy have not been established for children under 18.
Q: Can Omidria interact with non-sedating antihistamines?
Official product information notes that non-sedating antihistamines may interact with Omidria. These substances can sometimes affect pupil size, and their concurrent use may alter the magnitude of Omidria's pupil-dilating effect (mydriatic effect) during the procedure.
Q: What is the duration of the pain relief provided by Omidria?
Clinical studies designed to support the indication for the reduction of acute postoperative ocular pain evaluated the effect during the initial 10 to 12 hours following the procedure.
Q: Is Omidria a replacement for the eye drops typically used before or after cataract surgery?
Omidria is administered intraocularly (inside the eye) during the surgical procedure only. Official sources indicate that patients may still be prescribed other eye drops, commonly used before or after surgery, to help prevent infection or manage post-operative pain and inflammation.
Q: Is the phenylephrine component in Omidria the same as the ingredient found in some cold medicines?
Phenylephrine hydrochloride is the chemical name for the active ingredient that causes pupil dilation in Omidria. This same drug substance is found in many non-prescription cold and allergy medications.
Q: What is the risk of high blood pressure when Omidria is administered?
Regulatory documents indicate that the systemic exposure to the drug’s components is minimal. However, the phenylephrine component can cause transient elevations in blood pressure. Regulatory documents state that caution is required for patients with poorly controlled hypertension (high blood pressure) or other pre-existing cardiovascular issues.
Q: How does Omidria help to reduce eye pain after the operation?
Omidria's pain-reducing component is ketorolac, a Nonsteroidal Anti-inflammatory Drug (NSAID). The ketorolac component helps by reducing the production of certain signaling substances, called prostaglandins, that cause pain and inflammation after surgery.
Q: What is the difference between Omidria and compounded or separate topical drops for dilation and pain?
Omidria is an FDA-approved, fixed-dose combination product that is manufactured and tested under official regulatory standards. Compounded or separate topical drops are typically prepared in a pharmacy, and compounded medications are not subject to the same strict testing and evaluation process by official regulatory bodies as approved products.
Q: Are there any special warnings for patients with pre-existing heart conditions?
Yes. Due to the presence of phenylephrine, official product information advises caution for patients with poorly controlled hypertension and other pre-existing cardiovascular conditions. There is a rare, documented risk of serious cardiovascular reactions, including abnormal heart rhythms, associated with phenylephrine.
Q: Are there different doses of Omidria based on the patient's size or age?
The regulatory documents specify a standardized dilution regimen for a single surgical event. Official prescribing information states that no explicit dose adjustment or special considerations are anticipated or required for adult, elderly, or pediatric patients.
Q: Does Omidria affect the ability to drive or use machinery after the surgery?
Official documentation states that the medicine can have a major influence on the ability to drive and use machines. This is because the surgical procedure and the medicine may temporarily affect vision. Official documentation advises patients to refrain from driving or using machinery until their vision has cleared.
Q: Is the ketorolac component of Omidria associated with the same warnings as oral NSAIDs?
The ketorolac component, being an NSAID, carries a potential for cross-sensitivity to similar drugs like aspirin. Regulatory documents note that there have been reports of bronchospasm or the worsening of asthma associated with ketorolac in susceptible patients.
Q: Can a patient with an overactive thyroid gland (hyperthyroidism) receive Omidria?
Official product safety information advises that conditions like hyperthyroidism (overactive thyroid gland) and unstable cardiovascular disease should be addressed prior to surgery. This is due to the presence of phenylephrine, which may affect the cardiovascular system.
Q: Does Omidria help prevent complications like Intraoperative Floppy Iris Syndrome (IFIS)?
Official research evidence noted that studies examined the use of the drug in high-risk cases, such as those with IFIS (a complication of cataract surgery). While not an official indication, some studies have reported an association with a reduced incidence of IFIS symptoms and a larger average pupil diameter during surgery compared to a control group.
Q: Does Omidria have any effect on vision quality in the days following surgery?
Official documentation notes that vision may be temporarily affected following intraocular lens replacement. For this reason, patients are advised to refrain from activities like driving until their vision is clear. Any long-term effects on vision quality were not a primary finding of the core clinical trials.
Q: Why is Omidria not recommended for use during breastfeeding?
Official guidance is based on the general principle that many drugs can pass into human milk, and specific data regarding the product’s components in human milk are not available. For this reason, caution should be exercised when the product is administered to nursing women.
Q: Does Omidria cause the pupil to remain dilated for a long time after the surgery?
The pupil-dilating effect of the medicine is temporary. Patients are advised that their vision may be blurred and they should not drive or use machines until their vision has cleared, which is often several hours up to about a day after the procedure.
Q: What is the safety profile of Omidria in elderly patients?
The elderly population, defined as geriatric patients, was included in the clinical studies used to establish efficacy and safety. Regulatory documents state that no dose adjustment is required for geriatric patients compared to younger adults.
Q: Is Omidria used in all types of lens replacement surgery, or just cataracts?
Omidria is officially indicated for use during cataract surgery or intraocular lens replacement. This means its use is not limited strictly to cataract extraction but applies to the overall procedure of intraocular lens placement.
Q: Is it common to experience sensitivity to light after cataract surgery where Omidria was used?
A specific adverse reaction called photophobia (sensitivity to light) was observed in clinical trials. However, the frequency of this reaction was low and was reported similarly in patients who received the drug and those who received a placebo.
Q: Why do some doctors choose to use Omidria over other methods for pupil dilation?
Official clinical trials found that the combination solution maintained pupil size by preventing intraoperative miosis (pupil shrinking). Studies reported a statistically significantly lower percentage of subjects experienced miosis compared to those who received a placebo solution.
Q: What are the possible side effects for the eye itself, such as irritation or redness?
Common ocular adverse reactions reported in clinical trials include eye irritation and anterior chamber inflammation. Official labels also list effects such as conjunctival hyperaemia (eye redness) as a possible, but not guaranteed, adverse reaction.
Q: If a patient takes blood thinners, will Omidria affect their bleeding risk?
The ketorolac component, an NSAID, can affect platelet aggregation, which is related to bleeding. However, due to the minimal and transient systemic exposure following the intraocular route of administration, official documents conclude that drug interactions that alter blood levels are not expected.
_EN.png)
